US Representative

Gregory Pence 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 4)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB382

Introduced
1/17/23  
Refer
1/17/23  
Refer
1/27/23  
Pandemic is Over Act This bill terminates the COVID-19 public health emergency that was declared on January 31, 2020, on the date of the bill's enactment.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3882

Introduced
6/7/23  
Leveling the Playing Field 2.0 Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3949

Introduced
6/9/23  
Refer
6/9/23  
END CELLS in CELLS Act Eliminate Non-approved Devices and Contraband Electronics Limiting Links to Society in Confined Environments for Longer Lasting Safety Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4035

Introduced
6/12/23  
Protecting Small Business Information Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4157

Introduced
6/15/23  
Refer
6/15/23  
Not Just a Number Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB431

Introduced
1/20/23  
Life at Conception Act This bill declares that the right to life guaranteed by the Constitution is vested in each human being at all stages of life, including the moment of fertilization, cloning, or other moment at which an individual comes into being. Nothing in this bill shall be construed to authorize the prosecution of any woman for the death of her unborn child.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4531

Introduced
7/11/23  
Refer
7/11/23  
Report Pass
7/19/23  
Report Pass
9/28/23  
Support for Patients and Communities Reauthorization Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB467

Introduced
1/24/23  
Refer
1/24/23  
Refer
1/24/23  
Report Pass
3/24/23  
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB468

Introduced
1/24/23  
Refer
1/24/23  
Building America's Health Care Workforce Act This bill extends certain flexibilities relating to training and competency requirements for nurse aides in Medicare skilled nursing facilities (SNFs) and Medicaid nursing facilities (NFs). Generally, SNFs and NFs may not hire nurse aides for longer than four months unless they meet certain training and certification requirements. The Centers for Medicare & Medicaid Services waived some of these requirements during the COVID-19 emergency period so as to allow facilities to maintain adequate staffing levels; the blanket waiver ended in June 2022, though individual facilities, states, and counties may continue to apply for waivers during the emergency period. The bill extends these flexibilities for at least two years after the bill's enactment and specifies that (1) any time worked by a nurse aide during the emergency period counts toward the 75 hours required for initial training, and (2) a competency evaluation may be conducted at the SNF or NF where the nurse aide is employed if the state does not offer such an evaluation at least once a week.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4721

Introduced
7/18/23  
Main Street Tax Certainty Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4818

Introduced
7/20/23  
Refer
7/20/23  
Refer
7/21/23  
Treat and Reduce Obesity Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB497

Introduced
1/25/23  
Refer
1/25/23  
Engrossed
2/1/23  
Freedom for Health Care Workers Act This bill nullifies the rule titled Medicare and Medicaid Programs; Omnibus COVID-19 Health Care Staff Vaccination, which was issued by the Centers for Medicare & Medicaid Services on November 5, 2021, and prohibits the issuance of any substantially similar rule. The rule requires health care providers, as a condition of Medicare and Medicaid participation, to ensure that staff are fully vaccinated against COVID-19.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB5073

Introduced
7/28/23  
Promoting Domestic Energy Production Act

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4469

Introduced
7/6/23  
Refer
7/6/23  
Refer
7/7/23  
No Fuel Credits for Batteries Act of 2023